Identification of TIMP2 As a Prognostic Biomarker and Its Correlation with Tumor Immune Microenvironment: A Comprehensive Pan-Cancer Analysis

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Oct 28

PMID 36304987

Authors

Dan-Dan Wang

Wen-Xiu Xu

Wen-Quan Chen

Lei Li

Su-Jin Yang

Jian Zhang

Jin-Hai Tang

Affiliations

Soon will be listed here.

Abstract

Background: Tissue inhibitor of metalloproteinase-2 (TIMP2), an endogenous inhibitor of matrix metalloproteinases, has been disclosed to participate in the development and carcinogenesis of multiple malignancies. However, the prognosis of TIMP2 in different cancers and its correlation with tumor microenvironment and immunity have not been clarified.

Methods: In this study, we conducted a comprehensive bioinformatics analysis to evaluate the prognostic and therapeutic value of TIMP2 in cancer patients by utilizing a series of databases, including Oncomine, GEPIA, cBioPortal, GeneMANIA, Metascape, and Sangerbox online tool. The expression of TIMP2 in different cancers was analyzed by Oncomine, TCGA, and GTEx databases, and mutation status of TIMP2 in cancers was then verified using the cBioPortal database. The protein-protein interaction (PPI) network of the TIMP family was exhibited by GeneMANIA. The prognosis of TIMP2 in cancers was performed though the GEPIA database and Cox regression. Additionally, the correlations between TIMP2 expression and immunity (immune cells, gene markers of immune cells, TMB, MSI, and neoantigen) were explored using Sangerbox online tool.

Results: The transcriptional level of TIMP2 in most cancerous tissues was significantly elevated. Survival analysis revealed that an elevated expression of TIMP2 is associated with unfavorable survival outcome in multiple cancers. Enrichment analysis demonstrated the possible mechanisms of TIMPs and their associated genes mainly involved in pathways including extracellular matrix (ECM) regulators, degradation of ECM and ECM disassembly, and several other signaling pathways.

Conclusions: Our findings systematically dissected that TIMP2 is a potential prognostic maker in various cancers and use the inhibitor of TIMP2, which may be an effective strategy for cancer therapy to improve the poor cancer survival and prognostic accuracy, but concrete mechanisms need to be validated by subsequent experiments.

Citing Articles

The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review.

Chatzidavid S, Kontandreopoulou C, Giannakopoulou N, Diamantopoulos P, Stafylidis C, Kyrtsonis M Adv Hematol. 2024; 2024:1370364.

PMID: 38435839 PMC: 10907108. DOI: 10.1155/2024/1370364.

References

Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G . CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2018; 47(D1):D900-D908. PMC: 6324047. DOI: 10.1093/nar/gky939. View

Butler G, Butler M, Atkinson S, Will H, Tamura T, Schade van Westrum S . The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem. 1998; 273(2):871-80. DOI: 10.1074/jbc.273.2.871. View

Warde-Farley D, Donaldson S, Comes O, Zuberi K, Badrawi R, Chao P . The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010; 38(Web Server issue):W214-20. PMC: 2896186. DOI: 10.1093/nar/gkq537. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Pittayapruek P, Meephansan J, Prapapan O, Komine M, Ohtsuki M . Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis. Int J Mol Sci. 2016; 17(6). PMC: 4926402. DOI: 10.3390/ijms17060868. View

Srivastava P, Lone T, Kapoor R, Mittal R . Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res. 2012; 43(2):117-24. DOI: 10.1016/j.arcmed.2012.02.006. View

Seo D, Li H, Guedez L, Wingfield P, Diaz T, Salloum R . TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003; 114(2):171-80. DOI: 10.1016/s0092-8674(03)00551-8. View

Goodman A, Kato S, Bazhenova L, Patel S, Frampton G, Miller V . Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017; 16(11):2598-2608. PMC: 5670009. DOI: 10.1158/1535-7163.MCT-17-0386. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

10.

Aldous A, Dong J . Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Bioorg Med Chem. 2017; 26(10):2842-2849. DOI: 10.1016/j.bmc.2017.10.021. View

11.

Jackson H, Defamie V, Waterhouse P, Khokha R . TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2016; 17(1):38-53. DOI: 10.1038/nrc.2016.115. View

12.

Sbardella D, Fasciglione G, Gioia M, Ciaccio C, Tundo G, Marini S . Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. Mol Aspects Med. 2011; 33(2):119-208. DOI: 10.1016/j.mam.2011.10.015. View

13.

Wang W, Zhang Y, Liu M, Wang Y, Yang T, Li D . TIMP2 is a Poor Prognostic Factor and Predicts Metastatic Biological Behavior in Gastric Cancer. Sci Rep. 2018; 8(1):9629. PMC: 6018464. DOI: 10.1038/s41598-018-27897-x. View

14.

Rhodes D, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B . Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-80. PMC: 1813932. DOI: 10.1593/neo.07112. View

15.

Balachandran V, Luksza M, Zhao J, Makarov V, Moral J, Remark R . Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017; 551(7681):512-516. PMC: 6145146. DOI: 10.1038/nature24462. View

16.

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

17.

Peeney D, Fan Y, Nguyen T, Meerzaman D, Stetler-Stevenson W . Matrisome-Associated Gene Expression Patterns Correlating with TIMP2 in Cancer. Sci Rep. 2019; 9(1):20142. PMC: 6934702. DOI: 10.1038/s41598-019-56632-3. View

18.

Hegde P, Chen D . Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020; 52(1):17-35. DOI: 10.1016/j.immuni.2019.12.011. View

19.

Eckfeld C, Haussler D, Schoeps B, Hermann C, Kruger A . Functional disparities within the TIMP family in cancer: hints from molecular divergence. Cancer Metastasis Rev. 2019; 38(3):469-481. DOI: 10.1007/s10555-019-09812-6. View

20.

Cortes J, Perez-Garcia J, Llombart-Cussac A, Curigliano G, El Saghir N, Cardoso F . Enhancing global access to cancer medicines. CA Cancer J Clin. 2020; 70(2):105-124. DOI: 10.3322/caac.21597. View